| Aug 30 |
J&J targets generalised myasthenia gravis landscape with nipocalimab
|
| Aug 30 |
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
|
| Aug 30 |
J&J launches MatrixSternum fixation system for cardiac surgery in the US
|
| Aug 29 |
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
|
| Aug 29 |
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
|
| Aug 29 |
J&J submits FDA application for myasthenia gravis drug nipocalimab
|
| Aug 29 |
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
|
| Aug 29 |
J&J submits touted autoimmune disease drug for FDA approval
|
| Aug 29 |
Biocon Biologics signs agreement with Janssen to market Bmab 1200
|
| Aug 29 |
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
|
